Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY): $51.86

0.44 (+0.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNY POWR Grades


  • Stability is the dimension where SNY ranks best; there it ranks ahead of 96.36% of US stocks.
  • SNY's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • SNY ranks lowest in Momentum; there it ranks in the 11th percentile.

SNY Stock Summary

  • With a market capitalization of $128,621,016,471, Sanofi has a greater market value than 98.13% of US stocks.
  • Over the past twelve months, SNY has reported earnings growth of 138.44%, putting it ahead of 87.37% of US stocks in our set.
  • The volatility of Sanofi's share price is greater than that of merely 1.8% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are TGT, IBM, RTX, AMAT, and MMM.
  • SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.

SNY Stock Price Chart Interactive Chart >

Price chart for SNY

SNY Price/Volume Stats

Current price $51.86 52-week high $54.26
Prev. close $51.42 52-week low $44.76
Day low $51.50 Volume 2,024,600
Day high $52.15 Avg. volume 1,908,802
50-day MA $52.62 Dividend yield 2.64%
200-day MA $50.01 Market Cap 130.58B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$51.86$38.04 -29%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sanofi. To summarize, we found that Sanofi ranked in the 45th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for SNY, they are:

  • In the past 5 years, Sanofi has a compound free cash flow growth rate of 0%; that's higher than only 19.53% of free cash flow generating stocks in the Healthcare sector.
  • Sanofi's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 7.53% of tickers in our DCF set.
  • SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 7.53% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-31%
1%-30%
2%-29%
3%-29%
4%-28%
5%-27%

MCK, ADUS, INFU, REGN, and ABT can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Global Antibody Production Services Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer, Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Biogen, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Seattle Genetics

The report on Global Antibody Production Services Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []

Jumbo News | July 23, 2021

Global Edible Vaccine Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: GSK, Merial, Sanofi, Merck, Ceva, Santa Cruz Animal Health

The report on Global Edible Vaccine Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []

Jumbo News | July 23, 2021

Global Kidney Disease Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: GlaxoSmithKline, AbbVie, Pfizer, Sanofi, Kissei Pharmaceutical, Roche, Teva Pharmaceutical Industries, Keryx Biopharmaceuticals, AstraZeneca, Amgen, Changxing Pharmaceutical, Tianjin Tongrentang Group, zhejiang Shengbokang Pharmaceutical, Hebei Ruisen Pharmaceutical, Jiangxi Jimin Kexin J

The report on Global Kidney Disease Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []

Jumbo News | July 23, 2021

Global H1N1 Vaccines Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Abbott, Cipla, GSK, Baxter International, Hualan Biological Engineering, Sanofi, Sinovac Biotech, Mitsubishi Tanabe Pharma, Pfizer, Merck

The report on Global H1N1 Vaccines Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []

Jumbo News | July 23, 2021

Global Overactive Bladder (OAB) Therapeutics Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries

The report on Global Overactive Bladder (OAB) Therapeutics Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []

Jumbo News | July 23, 2021

Read More 'SNY' Stories Here

SNY Price Returns

1-mo -0.88%
3-mo 3.04%
6-mo 7.30%
1-year 4.11%
3-year 35.13%
5-year 46.21%
YTD 9.59%
2020 -0.83%
2019 23.73%
2018 4.20%
2017 8.73%
2016 -2.52%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9369 seconds.